EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alpine Immune Sciences's Enterprise Value is $4,159.40 Mil.
Alpine Immune Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-80.96 Mil. Therefore, Alpine Immune Sciences's EV-to-FCF for today is -51.37.
The historical rank and industry rank for Alpine Immune Sciences's EV-to-FCF or its related term are showing as below:
ALPN'
s EV-to-FCF Range Over the Past 10 Years
Min: -51.38 Med: -1.46 Max: 28.49
Current: -51.38
During the past 12 years, the highest EV-to-FCF of Alpine Immune Sciences was 28.49. The lowest was -51.38. And the median was -1.46.
ALPN's EV-to-FCF is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 7.545
vs ALPN: -51.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alpine Immune Sciences's EV-to-FCF
For the Biotechnology subindustry, Alpine Immune Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpine Immune Sciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alpine Immune Sciences's EV-to-FCF falls into.
Alpine Immune Sciences's current Enterprise Value is $4,159.40 Mil.
Alpine Immune Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alpine Immune Sciences's PE Ratio for today is calculated as:
Alpine Immune Sciences's share price for today is $64.955.
Alpine Immune Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alpine Immune Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Alpine Immune Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Alpine Immune Sciences (Alpine Immune Sciences) Business Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALPN has been successfully added to your 